Brief: Nicox: Mississippi Phase 2 Trial For NCX 4251 To Start In Dec 2020

Nicox SA

13/10/2020 06:35

Oct 13 (Reuters) - Nicox SA  NCOX.PA :
    * NICOX ANNOUNCES PLANS FOR NCX 4251 PHASE 2 TRIAL IN BLEPHARITIS
    * MISSISSIPPI PHASE 2 TRIAL WILL EVALUATE ONCE-DAILY DOSED NCX 4251 0.1% AGAINST PLACEBO IN
BLEPHARITIS PATIENTS
    * TRIAL IS TARGETED TO START IN DECEMBER 2020 WITH TOP-LINE RESULTS EXPECTED IN Q4 2021
    * IF PRIMARY ENDPOINT IS MET, TRIAL COULD COUNT AS ONE OF TWO PIVOTAL TRIALS REQUIRED FOR
APPROVAL
IN U.S.

Source text for Eikon:  ID:nGNX4L8xck 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))